Pituitary Neoplasms: Clinical Trials

12 trials for Pituitary Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 12 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 6, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 22Completed 1, Unknown 1

Follow Pituitary Neoplasms: new trials by email Literature Review of Pituitary Neoplasms trials Research Report on Pituitary Neoplasms

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours
Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease
Phase 3Not yet recruitingUniversity College, London822026-09-012026-10-01
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas
Cabergoline - Prolactinoma, Prolactin Excess
Phase 3RecruitingUniversity of Sao Paulo General Hospital702026-03-042026-03-13
The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas
Radiotherapy plus temozolomide, Radiotherapy plus placebo - Pituitary Adenomas
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital1502020-02-102020-01-28
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection - Acromegaly Due to Pituitary Adenoma
Phase 3UnknownSamsung Medical Center902018-03-012018-03-01
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Pasireotide LAR - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals1232015-03-312019-12-10
Cabergoline in Nonfunctioning Pituitary Adenomas
Cabergoline - Pituitary Adenoma, Nonfunctioning Pituitary Adenoma
Phase 3CompletedUniversity of Sao Paulo General Hospital1402015-02-012017-09-07
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Gallium-68 DOTATOC PET - Pituitary Tumours
Phase 3TerminatedGöteborg University222015-01-012022-03-31
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas
cabergoline - Pituitary Neoplasms, Adenoma
Phase 3Active not recruitingSt. Olavs Hospital602014-11-012026-07-21
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Pasireotide sub-cutaneous - Cushing's Disease
Phase 3CompletedNovartis Pharmaceuticals1042011-08-162018-06-19
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals1982010-07-192018-04-05
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Pasireotide, cabergoline - Non-functioning Pituitary Adenomas, Prolactinomas
Phase 2 / Phase 3CompletedUniversidade Federal do Rio de Janeiro212010-03-012016-08-22
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Cabergoline - Cushing's Disease, Corticotroph Adenoma
Phase 3CompletedSeth Gordhandas Sunderdas Medical College2007-11-012009-04-29

Narrower conditions

Acromegaly (5)  ·  Pituitary ACTH Hypersecretion (3)  ·  Adenoma (2)  ·  Growth Hormone-Secreting Pituitary Adenoma (2)  ·  Pituitary Diseases (2)  ·  Prolactinoma (2)  ·  ACTH-Secreting Pituitary Adenoma (1)  ·  Gigantism (1)  ·  Growth Disorders (1)  ·  Hyperprolactinemia (1)

Broader conditions

Brain Diseases (12)  ·  Central Nervous System Diseases (12)  ·  Endocrine Gland Neoplasms (12)  ·  Endocrine System Diseases (12)  ·  Hypothalamic Diseases (12)  ·  Neoplasms (12)  ·  Neoplasms by Site (12)  ·  Nervous System Diseases (12)  ·  Pituitary Diseases (10)  ·  Brain Neoplasms (9)  ·  Central Nervous System Neoplasms (9)  ·  Hypothalamic Neoplasms (9)  ·  Nervous System Neoplasms (9)  ·  Supratentorial Neoplasms (9)  ·  Hyperpituitarism (8)

Interventions

Cabergoline (5)  ·  pasireotide (3)  ·  Injections (1)  ·  Proton Therapy (1)  ·  Radiosurgery (1)  ·  Radiotherapy (1)  ·  Radiotherapy, Intensity-Modulated (1)  ·  Solutions (1)  ·  Temozolomide (1)  ·  lanreotide (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  University of Sao Paulo General Hospital (2)  ·  Göteborg University (1)  ·  Peking Union Medical College Hospital (1)  ·  Samsung Medical Center (1)  ·  Seth Gordhandas Sunderdas Medical College (1)  ·  St. Olavs Hospital (1)  ·  Universidade Federal do Rio de Janeiro (1)  ·  University College, London (1)

Countries

Brazil (6)  ·  Romania (3)  ·  Argentina (2)  ·  Belgium (2)  ·  Colombia (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Norway (2)  ·  Russia (2)  ·  South Korea (2)  ·  Spain (2)  ·  Sweden (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)

Top investigators

Michael Kosmin (1)  ·  Nalini S Shah, DM (1)  ·  Rafael L Batista, MD (1)  ·  Sven M Carlsen, prof md (1)

Results publications

PMID 25260838, PMID 25418156, PMID 27150495, PMID 30540568, PMID 31379734, PMID 32117045, PMID 32217809, PMID 35954244, PMID 36856733

NIH funding

2014 (1)